Vaginal moisture and lubrication depend on estrogen. Estrogen maintains the thickness, elasticity, and secretory capacity of the vaginal epithelium, the vasocongestion response that produces lubrication with arousal, and the normal vaginal pH that supports healthy flora. When estrogen is reduced from any cause, vaginal dryness follows.
Menopause is the most sustained and progressive cause of estrogen deficiency and vaginal dryness — and the dedicated page on this topic within our Menopause cluster covers it in full depth. But vaginal dryness also occurs in breastfeeding women, women on certain hormonal contraceptives that suppress ovarian estrogen, women receiving cancer treatment, and women with autoimmune conditions affecting the vaginal glands. For these women, the dryness is fully reversible when the underlying cause is addressed or when appropriate local treatment is provided.
Menopause and Perimenopause
The most common and progressive cause of vaginal dryness. Declining estrogen during perimenopause and the sustained estrogen deficiency of postmenopause produce genitourinary syndrome of menopause — a progressive condition that worsens without treatment and affects vaginal, vulvar, and urethral tissue simultaneously. Unlike vasomotor symptoms, vaginal dryness from menopause does not improve spontaneously over time. Full GSM detail page →
Breastfeeding
Breastfeeding suppresses ovarian estrogen production through elevated prolactin levels, producing a hypoestrogenic state that can be as significant as early menopause in its vaginal effects. Vaginal dryness, reduced lubrication, and pain with intercourse during the postpartum breastfeeding period are common, underrecognized, and directly attributable to lactation-induced estrogen suppression. Local vaginal estrogen at low doses is compatible with breastfeeding and significantly improves vaginal symptoms without affecting milk production or infant health.
Hormonal Contraception
Certain hormonal contraceptives — particularly combined oral contraceptives containing certain progestins and low-dose estrogen formulations, as well as progestin-only methods — suppress ovarian estrogen production or reduce free estrogen bioavailability in ways that produce vaginal dryness and reduced arousal lubrication in susceptible women. Women who develop vaginal dryness or pain with intercourse after starting a hormonal contraceptive should discuss the specific formulation and its hormonal profile at a gynecologic evaluation, as switching to a different formulation often resolves the issue.
Cancer Treatment
Chemotherapy, pelvic radiation, and hormonal treatments for breast cancer (aromatase inhibitors, tamoxifen) produce vaginal dryness through different mechanisms but with similar clinical effects. Aromatase inhibitors used for postmenopausal breast cancer produce profound estrogen deficiency that is often more severe in its vaginal effects than natural menopause. The management of vaginal dryness in women with a history of breast cancer requires individualized discussion about local vaginal estrogen appropriateness alongside non-estrogen options.
Sjögren’s Syndrome and Autoimmune Conditions
Sjögren’s syndrome, an autoimmune condition that primarily targets secretory glands, produces dryness of the vaginal mucosa and Bartholin glands alongside the characteristic dry eyes and dry mouth. Vaginal dryness in Sjögren’s reflects glandular dysfunction rather than estrogen deficiency, though local estrogen therapy can still improve epithelial thickness and moisture and is appropriate for eligible patients.
Non-Prescription Measures
Vaginal moisturizers applied regularly (2-3 times per week) and lubricants used during intercourse provide meaningful symptom relief for mild to moderate dryness from any cause. These are appropriate first-line measures while hormonal causes are being assessed and as adjuncts to hormonal treatment.
Local Vaginal Estrogen
Low-dose local vaginal estrogen restores epithelial thickness and moisture with minimal systemic absorption. It is effective for vaginal dryness from menopause, breastfeeding-associated dryness, and in many cases hormonal contraception-related dryness. Its appropriateness for women with breast cancer history requires individualized clinical discussion.
Non-Estrogen Prescription Options
Ospemifene (Osphena) and prasterone (Intrarosa) provide vaginal tissue improvement for women who prefer to avoid estrogen. For breastfeeding women, addressing the breastfeeding-associated estrogen suppression through the treating provider may allow dryness to resolve as breastfeeding is modified or discontinued. For contraception-related dryness, reformulation is often the most direct solution.
Vaginal dryness that is making intimacy painful, producing daily discomfort, or affecting your quality of life has effective treatment options whether you are 28 and breastfeeding, 35 and on hormonal contraception, 45 and in perimenopause, or 65 and postmenopausal. The right treatment depends on the cause and your health history — and that is exactly what a gynecologic evaluation clarifies.
Dr. Ramona D. Andrei and the team at Lapeer Women’s Health are here for that evaluation — at both our Lapeer and Rochester Hills offices, without a referral required.
Our team at Lapeer Women’s Health provides hormonal and non-hormonal options at both our Lapeer and Rochester Hills offices. No referral required.
Schedule a Gynecologic VisitEducational purposes only. Not medical advice. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.
Gynecologic care for women of every age
Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307
Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.